Advertisement

Topics

Challenge the Buyout: Ademi & O’Reilly, LLP Investigates Whether Rentech Nitrogen Partners, L.P. Has Obtained a Fair Price in Its Sale to CVR Partners

20:00 EDT 9 Aug 2015 | Globe Newswire

MILWAUKEE, Aug. 10, 2015 (GLOBE NEWSWIRE) -- We are investigating the Board of Directors of Rentech for possible breaches of fiduciary duty and other violations of state law in connection with the sale of Rentech to CVR.

Click here to learn how to join the action: http://www.ademilaw.com/case/rentech or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Rentech’s long-term financial outlook is positive and yet shareholders will receive only 1.04 units of CVR Partners and $2.57 cash for each Rentech unit held.  CVR is well aware of Rentech’s improving financial metrics and is purchasing Rentech at a substantial discount.  The merger agreement unreasonably limits prospective bids by (i) prohibiting solicitation of any further bids, and (ii) imposing a termination penalty should Rentech receive and accept a superior bid.  Rentech’s insiders and their affiliates own significant stock, and will receive millions of dollars as part of change of control arrangements. These insiders can unduly influence a sale of Rentech, which may not be in the best interests of non-insider shareholders. Our investigation centers on the conduct of Rentech’s Board of Directors, who have unanimously approved the transaction, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Rentech given its current financial condition and prospects. 

If you own units of Rentech and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, http://www.ademilaw.com/case/Rentech.                                 

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country.  For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.


 

Contact:
Ademi & O’Reilly, LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
NEXT ARTICLE

More From BioPortfolio on "Challenge the Buyout: Ademi & O’Reilly, LLP Investigates Whether Rentech Nitrogen Partners, L.P. Has Obtained a Fair Price in Its Sale to CVR Partners"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...